Advanced in Obesity

Simiso M. Sokhela

Johannesburg, GT, ZA 
Advanced in Obesity
Johannesburg, GT, ZA 
OverviewLocationsClinical Research

Overview

Simiso Sokhela practices in Johannesburg, South Africa. Sokhela is rated as an Advanced expert by MediFind in the treatment of Obesity. Their top areas of expertise are HIV/AIDS, Obesity, Severe Acute Respiratory Syndrome (SARS), and Woods Black Norbury Syndrome.

Their clinical research consists of co-authoring 47 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Obesity.

Locations

Johannesburg, GT, South Africa
Other Locations
South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa
A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa
Enrollment Status: Completed
Publish Date: August 03, 2023
Intervention Type: Drug
Study Drug: Doravirine+Lamivudine+Tenofovir Disoproxil Fumarate
Study Phase: Phase 3
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir, Tenofovir Alafenamide, Truvada, Atripla
Study Phase: Phase 3
A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)
A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)
Enrollment Status: Completed
Publish Date: July 14, 2022
Intervention Type: Drug
Study Drug: DuACT
Study Phase: Phase 2
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: Nitazoxanide, Sofosbuvir/Daclatasvir
Study Phase: Phase 2
View 4 Less Clinical Trials

47 Total Publications

REPRIEVE final results: What does it mean for guidelines in low- and middle-income countries?
REPRIEVE final results: What does it mean for guidelines in low- and middle-income countries?
Journal: Journal of the International AIDS Society
Published: December 28, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sokhela's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile